Barclays
NGNE icon

Barclays’s Neurogene NGNE Stock Holding History

Barclays’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$104K Buy
3,310
+559
+20% +$15.4K ﹤0.01% 4024
2026
Q1 		$55.5K Sell
2,751
-12,624
-82% -$245K ﹤0.01% 4279
2025
Q4 		$317K Buy
15,375
+448
+3% +$11.2K ﹤0.01% 4103
2025
Q3 		$259K Sell
14,927
-3,084
-17% -$61.9K ﹤0.01% 4178
2025
Q2 		$269K Buy
18,011
+3,782
+27% +$59.3K ﹤0.01% 4102
2025
Q1 		$167K Sell
14,229
-3,304
-19% -$57.4K ﹤0.01% 4146
2024
Q4 		$401K Buy
17,533
+2,674
+18% +$99.5K ﹤0.01% 3959
2024
Q3 		$623K Buy
14,859
+11,316
+319% +$439K ﹤0.01% 3639
2024
Q2 		$129K Sell
3,543
-8,457
-70% -$298K ﹤0.01% 3789
2024
Q1 		$611K Buy
+12,000
New +$401K ﹤0.01% 3466
2023
Q3 		– Sell
-8
Closed -$135 – 4667
2023
Q2 		$135 Sell
8
-257
-97% -$4.21K ﹤0.01% 4432
2023
Q1 		$3.7K Sell
265
-22,348
-99% -$262K ﹤0.01% 4853
2022
Q4 		$230K Hold
22,613
– – ﹤0.01% 3765
2022
Q3 		$289K Hold
22,613
– – ﹤0.01% 2996
2022
Q2 		$466K Sell
22,613
-285
-1% -$6.95K ﹤0.01% 2915
2022
Q1 		$861K Buy
+22,898
New +$1.34M ﹤0.01% 2525
2019
Q1 		– Sell
-480
Closed -$21K – 7221
2018
Q4 		$21K Sell
480
-400
-45% -$19.5K ﹤0.01% 5876
2018
Q3 		$52K Buy
+880
New +$51.9K ﹤0.01% 6058
2018
Q2 		– Sell
-3
Closed -$782 – 7172
2018
Q1 		$1K Hold
3
– – ﹤0.01% 6963
2017
Q4 		$1K Buy
+3
New +$703 ﹤0.01% 6848
2017
Q3 		– Sell
-10
Closed -$3K – 6972
2017
Q2 		$3K Buy
10
+1
+11% +$286 ﹤0.01% 6351
2017
Q1 		$3K Sell
9
-42
-82% -$14.8K ﹤0.01% 6391
2016
Q4 		$16K Buy
51
+18
+55% +$4.84K ﹤0.01% 5727
2016
Q3 		$9K Buy
33
+22
+200% +$4.43K ﹤0.01% 5832
2016
Q2 		$1K Buy
11
+5
+83% +$795 ﹤0.01% 6132
2016
Q1 		$1K Sell
6
-8
-57% -$1.55K ﹤0.01% 5983
2015
Q4 		$3K Buy
+14
New +$3.68K ﹤0.01% 5682

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Barclays's NGNE Position: Q2 2026 in Review

Barclays increased its Neurogene (NGNE) stake by 20% in Q2 2026, buying an estimated $15.4K and bringing the position to 3,310 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #4024.

Barclays first reported a position in NGNE in Q4 2015 and has held it in 27 quarters since. The position peaked at $861K in Q1 2022. 112 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Barclays held 3,310 shares of Neurogene worth $104K as of Q2 2026.
  • Barclays bought 559 Neurogene shares in Q2 2026, an estimated $15.4K.
  • Neurogene made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4024 holding.
  • Barclays first reported a position in Neurogene in Q4 2015 and has held it in 27 quarters since.
  • Barclays's Neurogene position peaked at $861K in Q1 2022.
  • 112 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.